1224 related articles for article (PubMed ID: 32327243)
1. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
2. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M
Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
[TBL] [Abstract][Full Text] [Related]
3. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
5. Association between blood transfusion after kidney transplantation and risk for the development of de novo HLA donor-specific antibodies and poor clinical outcomes: A single-center retrospective study.
Kang ZY; Liu C; Liu W; Li D
Transpl Immunol; 2023 Dec; 81():101930. PubMed ID: 37730183
[TBL] [Abstract][Full Text] [Related]
6. Association between longer hospitalization and development of
Yazawa M; Cseprekal O; Helmick RA; Talwar M; Balaraman V; Podila PSB; Fossey S; Satapathy SK; Eason JD; Molnar MZ
Ren Fail; 2020 Nov; 42(1):40-47. PubMed ID: 31875761
[No Abstract] [Full Text] [Related]
7. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
8. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
[TBL] [Abstract][Full Text] [Related]
9. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
Abuhelaiqa E; Friedlander R; Aull M; Putheti P; Sharma V; Suthanthiran M; Dadhania D
Clin Transpl; 2016; 32():83-91. PubMed ID: 28564525
[TBL] [Abstract][Full Text] [Related]
10. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
11. Non-HLA Antibodies and Epitope Mismatches in Kidney Transplant Recipients With Histological Antibody-Mediated Rejection.
Crespo M; Llinàs-Mallol L; Redondo-Pachón D; Butler C; Gimeno J; Pérez-Sáez MJ; Burballa C; Buxeda A; Arias-Cabrales C; Folgueiras M; Sanz-Ureña S; Valenzuela NM; Reed EF; Pascual J
Front Immunol; 2021; 12():703457. PubMed ID: 34305943
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
13. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
[TBL] [Abstract][Full Text] [Related]
14. Donor specific HLA antibodies & allograft injury: mechanisms, methods of detection, manifestations and management.
McCaughan JA; Tinckam KJ
Transpl Int; 2018 Oct; 31(10):1059-1070. PubMed ID: 30062683
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
Ginevri F; Nocera A; Comoli P; Innocente A; Cioni M; Parodi A; Fontana I; Magnasco A; Nocco A; Tagliamacco A; Sementa A; Ceriolo P; Ghio L; Zecca M; Cardillo M; Garibotto G; Ghiggeri GM; Poli F
Am J Transplant; 2012 Dec; 12(12):3355-62. PubMed ID: 22959074
[TBL] [Abstract][Full Text] [Related]
16. Effect of blood transfusion post kidney transplantation on de novo human leukocytes antigen donor-specific antibody development and clinical outcomes in kidney transplant recipients: A systematic review and meta-analysis.
Kang ZY; Ma S; Liu W; Liu C
Transpl Immunol; 2023 Jun; 78():101801. PubMed ID: 36841513
[TBL] [Abstract][Full Text] [Related]
17. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
[TBL] [Abstract][Full Text] [Related]
18. Impact of donor-specific antibody with low mean fluorescence intensity on allograft outcomes in kidney transplant.
Kitpermkiat R; Kantachuvesiri S; Thotsiri S; Thammanichanond D; Rostaing L; Wiwattanathum P
Transpl Immunol; 2024 Jun; 84():102054. PubMed ID: 38750972
[TBL] [Abstract][Full Text] [Related]
19. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
[TBL] [Abstract][Full Text] [Related]
20. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
